Trondheim

• HOVON 169 CAD: Phase II trial of Zanubrutinib in primary Cold Agglutinin Disease. CaZa study Ended recruitment
  2023-505746-25-00 4 2024-07-16 Cold agglutinin disease
• TALTEC: A phase II study measuring MRD negativity after bispecific T-cell redirectors TALquetamab and TEClistamab consolidation as part of f … Ended recruitment
  2023-508212-38-00 4 2024-06-11 Multiple Myeloma
• Testing LADA diabetes status 3 years after treatment with intranodal GAD-alum. Ended recruitment
  2023-509021-53-00 4 2024-06-05 Latent Autoimmune Diabetes in Adults (LADA)
• Comparison between rituximab plus zanubrutinib versus rituximab monotherapy in untreated splenic marginal zone lymphoma patients Ended recruitment
  2023-503755-10-00 5 2024-05-17 Splenic marginal zone lymphoma
• Efficacy, Safety, and Pharmacokinetics of Guselkumab in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis Ended recruitment
  2022-502238-22-00 5 2024-05-14 Ulcerative Colitis
• A study to determine if ALXN2220 is effective, safe, and tolerable in adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Ended recruitment
  2023-506669-70-00 5 2024-04-30 Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM).
• A Study of Mirikizumab (LY3074828) in Pediatric Participants with Crohn’s Disease (AMAY) Ended recruitment
  2024-511472-32-00 5 2024-03-12 Crohn's Disease
• A study of sigvotatug vedotin versus docetaxel in previously treated non-small cell lung cancer (Be6A Lung-01) Ended recruitment
  2023-503827-25-01 5 2024-02-16 Non-Small Cell Lung Cancer (NSCLC)
• A study to test the effect of BI 456906 on cardiovascular safety in people with overweight or obesity Ended recruitment
  2022-502442-27-00 5 2024-01-08 Obesity
• Phase II multicenter clinical trial: Mosunetuzumab for early relapse of follicular lymphoma in the Nordic countries (MERLIN/NLG-FL6/ML43841) Ended recruitment
  2022-500100-21-01 4 2023-09-11 Follicular lymphoma
• A double-blind randomized placebo-controlled four-arm trial to assess the efficacy of oral bicarbonate and intravenous butylscopolamine brom … Ended recruitment
  2024-511848-55-00 5 2023-01-03 childbirth
• METIMMOX-2: Oxaliplatin Chemotherapy and Immunotherapy to Patients with the Common pMMR/MSS Type of Large Bowel Cancer Spread to Other Organ … Ended recruitment
  2022-500027-76-00 4 2022-10-05 Colorectal cancer
• A clinical study that compares a treatment with Iberdomide, Daratumumab and Dexamethasone against a treatment with Daratumumab, Bortezomib, … Ended recruitment
  2024-510800-35-00 5 2022-06-17 Relapsed or Refractory Multiple Myeloma (RRMM)
• Is there a survival benefit of administering thoracic radiotherapy concurrently with immunnotherapy and chemotherapy for patients with exten … Ended recruitment
  2023-505514-15-00 5 2022-01-11 Small-cell lung cancer, extensive stage
• Acalabrutinib and rituximab in elderly patients with untreated mantle cell lymphoma (ALTAMIRA) Ended recruitment
  2023-509864-96-00 4 2021-12-07 Mantle Cell Lymphoma (MCL)
• MagnetisMM-5: A Phase 3 Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dex … Ended recruitment
  2023-509208-14-00 5 2021-09-28 MULTIPLE MYELOMA
• The ExPlas Study Ended recruitment
  2024-518668-11-01 4 2021-09-17 Early symptomatic phase Alzheimer's disease
• The REST (Replacing Steroids in the transplant ineligible) study. Ended recruitment
  2023-510194-34-00 4 2021-06-18 Multiple myeloma
• A Phase 3 study of Tafasitamab plus Lenalidomide in addition to Rituximab, versus Lenalidomide plus Rituximab in patients With Relapsed/Refr … Ended recruitment
  2023-504684-16-00 5 2021-06-05 follicular lymphoma (FL) and marginal zone lymphoma (MZL)
• An Open-label, Randomized Phase 3 Study of Immune and Targeted Combination Therapies, as First-line Treatment in Participants with Advanced … Ended recruitment
  2022-502122-41-00 5 2021-05-11 Clear cell renal cancer
• A study of patients with colorectal cancer that have a genetic abnormality in the BRAF gene taking encorafenib plus cetuximab with or withou … Ended recruitment
  2023-509405-77-00 5 2021-02-16 Colorectal cancer (BRAF V600E-mutant mCRC)
• A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab … Ended recruitment
  2022-500439-35-00 5 2021-02-11 treatment-naive chronic lymphocytic leukemia
• A Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in R/R DLBCL Ended recruitment
  2023-504830-23-00 5 2020-12-16 B-cell Lymphoma
• Ocrelizumab VErsus Rituximab off-Label at the Onset of Relapsing MS Disease (OVERLORD-MS) Ended recruitment
  2024-510716-71-00 5 2020-10-21 Multiple Sclerosis

Showing 121–144 of 183 trials